ARTICLES BY ED MISETA

• How BMS Uses AI To Improve Study Design And Reduce Costs

  1/19/2023

  In 2022, Bristol Myers Squibb (BMS) announced plans to work with AI developer Owkin to design and optimize cardiovascular drug trials. The partnership will allow BMS to use machine learning to enhance clinical trial design and execution.

• Clinical Sites Are Optimistic, Despite Growing Challenges

  1/17/2023

  The last few years have not been easy for sites involved with conducting clinical research. The onset of the pandemic in 2020 created numerous challenges, including the implementation of new technologies and operating models, the leveraging of remote staff, and virtual facilities. Despite the ongoing challenges, global sites remain optimistic about the future of clinical trials.

• How One Pharma Company Is Embracing Digital Technologies

  12/21/2022

  The increased demand for hybrid and decentralized approaches to clinical trials has increased the use of digital devices and other tools that will make studies more patient centric. Sanofi is one of the companies leading the way in getting devices into the hands of patients.

• The Future Of TransCelerate: Clinical Trial Modernization

  12/19/2022

  In January 2023, Janice Chang will take over as the head of industry consortia non-profit organization TransCelerate. Chang has been involved with TransCelerate since it was just a concept, and notes the time spent in the group since its launch has been an amazing journey.

• Boehringer Ingelheim Implements One Medicine Technology Platform

  12/8/2022

  For years, Boehringer Ingelheim operated with a system comprised of best-of-breed solutions from different vendor companies. After carefully evaluating the technology environment, the company decided to move from best-of-breed solutions to an end-to-end product development platform.

• AstraZeneca Hopes To Advance Oncology RWE

  12/6/2022

  AstraZeneca is an emerging leader in the chronic lymphocytic leukemia space. It now hopes to develop treatments so patients can avoid chemotherapy, with the hope those therapies will prolong survival in patients while also producing a better quality of life.

• What Astellas Has Learned About Decentralized Trials

  11/28/2022

  When the COVID pandemic hit in the spring of 2020, many companies were unprepared for the changes that were about to impact their studies. Astellas is one company that was better prepared than most. The company had initiated a formalized, internal project on decentralized clinical trial (DCT) technologies and their use in clinical trials about nine months prior to the pandemic.

• What Your Sites Love And Hate About DCTs

  10/25/2022

  For years, sponsor companies have had access to new and emerging technologies that would ease the participation burden of patients in clinical trials. While these emerging technologies helped sponsor companies keep their trials on track, they have also been a burden for the clinical sites having to deal with the changes required to keep up with them. Do you know where your sites stand on the adoption of hybrid trials and DCTs?

• Walgreens Is Ready To Re-Envision Recruitment, DCTs, And RWE

  9/12/2022

  Since becoming CEO of Walgreens Boots Alliance (WBA) in March 2021, Rosalind Brewer has been focused on healthcare and what the company could do to help its patients. WBA refers to the integrated healthcare, pharmacy, and retail store that currently serves millions of customers and patients every day. This past June, the company launched its clinical trial business. 

• Digital Solutions, Technology, And Patient Care Top Life Science Trends

  9/6/2022

  Technology company Within3 has produced a paper on the six top trends that are going to impact the pharmaceutical space. It’s no surprise that technology solutions were one of the trends making the list, but also included were factors such as patients, cyber threats, and a growing global marketplace.

• Tufts Finds Substantial Net Benefits To Using Decentralized Trials

  7/28/2022

  For years, vendors have touted decentralized clinical trials (DCTs) as a solution to both the time and cost challenges. DCTs also promise to make trials more patient centric. Unfortunately, a demonstration of the actual benefits of DCTs, along with a quantifiable dollar amount, have been difficult to produce. Until now.

• CVS Health Wants To Be Your New Clinical Research Site

  7/6/2022

  CVS has been a well-regarded and recognized healthcare brand that started as a pharmacy but has since migrated into a recognized and trusted healthcare company. Now CVS is hoping to expand the relationship it has with patients by moving closer into primary care and clinical trials.

• Takeda Takes A Strategic Approach To TMF

  6/21/2022

  Over the past five years, Takeda has been perfecting its all-in model for TMF, where both Takeda and its CRO partners collaborate in Takeda's eTMF. This enables transparency into TMF health across the partnership and drives more effective, proactive collaboration.

• How To Operationalize Diversity In Clinical Trials

  5/31/2022

  Changes are quickly taking place regarding the push for patient diversity in clinical trials. For years, sponsor companies have been trying to increase the number of ethnic and diverse patients in their studies. Soon, they will face tougher oversight. Here is how one company is overcoming the challenge.

• What Does The Future Hold For Decentralized Clinical Trials?

  4/20/2022

  What can we expect to see from decentralized trials in the next three years, and what are the challenges sponsor companies will need to overcome? A webinar hosted by IBM Watson hoped to answer that question and many others.